1Molecular Epidemiology and Predictive Tumor Markers Group, Area 3,Ramón y Cajal Health Research Institute (IRYCIS), 2The Biomedical Research Network in Cancer (CIBERONC), 3Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678),Ramón y Cajal Health Research Institute (IRYCIS), 4Faculty of Medicine,University of Alcalá de Henares, 5Institute of Tissue Medicine and Pathology,University of Bern, 6Department of Molecular Oncology, Cancer Research Institute,Biomedical Research Center of the Slovak Academy of Sciences, 7Experimental Oncology, Molecular Oncology Program,Centro Nacional de Investigaciones Oncológicas (CNIO), 8Department of Surgical Oncology, National Cancer Institute,Slovak Medical University, 9Pancreatic and Biliopancreatic Surgery Unit,Hospital Universitario Ramón y Cajal, 10Department of Pathology,Hospital Universitario Ramón y Cajal, 11Department of Radiation Oncology,Hospital Universitario Ramón y Cajal, 12Department of Cancer,Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), 13Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3,IRYCIS
Tumor organoids have revolutionized cancer research and the approach to personalized medicine. They represent a clinically relevant tumor model that allows researchers to stay one step ahead of the tumor in the clinic. This protocol establishes tumor organoids from fresh pancreatic tumor tissue samples and patient-derived xenografts of pancreatic adenocarcinoma origin.
